基于多参数MRI影像组学与深度学习预测高危多发性骨髓瘤的研究
Predicting High-Risk Multiple Myeloma Based on Multiparametric MRI Radiomics and Deep Learning
摘要: 目的:本研究旨在构建基于多参数MRI的影像组学模型、深度学习模型及影像组学深度学习联合模型,并评估不同模型预测高危多发性骨髓瘤的效能。方法:本研究回顾性收集了青岛大学附属医院从2014年5月至2025年3月经病理确诊的140例多发性骨髓瘤脊椎MRI图像,共258个病变,按照8:2的比例随机分为训练集(n = 206)、验证集(n = 52)。基于MRI常规序列矢状位T1WI、T2WI和FS-T2WI图像,使用ITK-SNAP软件对最大病灶累及椎体逐层勾画感兴趣区(Region of interest, ROI),人工提取影像组学特征,并采用2.5D Densenet169深度学习模型自动提取深度学习特征,分别构建影像组学模型和深度学习模型,然后通过多元逻辑回归将选择的影像组学特征和深度学习特征融合构建影像组学深度学习联合模型。采用受试者工作特征曲线(Operating characteristics curve, ROC)、曲线下面积(Area under curve, AUC)、灵敏度、特异度和准确度评估影像组学模型、深度学习模型和影像组学深度学习联合模型的预测效能。采用决策曲线分析(Decision curve analysis, DCA)比较三种模型在不同决策阈值下的净获益。结果:最终选择了4个影像组学特征和1个深度学习特征构建影像组学深度学习联合模型。影像组学深度学习联合模型的AUC值(训练集:0.996;验证集:0.893)高于影像组学模型和深度学习模型。决策曲线分析结果显示影像组学深度学习联合模型在预测高危多发性骨髓瘤方面具有更好的临床适用性。结论:影像组学深度学习联合模型在预测高危多发性骨髓瘤方面相较于其他两种模型具有更好的效能,有助于制定临床治疗策略。
Abstract: Objective: This study aimed to construct radiomics models, deep learning models, and integrated radiomics-deep learning models based on multiparametric MRI, and to evaluate the performance of different models in predicting high-risk multiple myeloma. Methods: This study retrospectively collected 140 patients in the Affiliated Hospital of Qingdao University from May 2014 and March 2025, including 258 vertebral lesions, all patients were pathologically confirmed multiple myeloma. The lesions were randomly divided into training (n = 206) and validation (n = 52) sets at an 8:2 ratio. Based on conventional MRI sequence, including sagittal T1-weighted imaging(T1WI), T2-weighted imaging (T2WI), and fat-suppressedT2-weighted imaging (FS-T2WI). The ROI was manually segmented on the largest lesion-involved vertebral body using ITK-SNAP software. Radiomics features were manually extracted, while a 2.5D DenseNet169 deep learning model was employed to automatically extract deep learning features. Separate radiomics and deep learning models were constructed, followed by an integrated radiomics-deep learning model developed by combining selected features through multivariate logistic regression. The predictive efficiency of the radiomics, deep learning, and integrated models was evaluated using receiver operating characteristic curves (ROC), area under the curve (AUC), sensitivity, specificity, and accuracy. Decision curve analysis (DCA) was applied to compare the net benefits of the three models across different decision thresholds. Results: A combined radiomics-deep learning model was constructed using four radiomic features and one deep learning feature. The AUC values of the combined radiomics-deep learning model (training set: 0.996; validation set: 0.893) were higher than those of the radiomics model and the deep learning model. Decision curve analysis results demonstrated that the combined radiomics-deep learning model has better clinical applicability in predicting high-risk multiple myelomacon. Conclusion: The integrated radiomics-deep learning model demonstrated superior performance in predicting high-risk multiple myeloma compared to the other two models, suggesting its potential for guiding clinical treatment strategies.
文章引用:张清源, 王瑶, 孙丽, 邵雅静, 高传平. 基于多参数MRI影像组学与深度学习预测高危多发性骨髓瘤的研究[J]. 临床医学进展, 2026, 16(1): 2611-2621. https://doi.org/10.12677/acm.2026.161321

参考文献

[1] Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef] [PubMed]
[2] Wu, Z., Bian, T., Dong, C., Duan, S., Fei, H., Hao, D., et al. (2022) Spinal MRI-Based Radiomics Analysis to Predict Treatment Response in Multiple Myeloma. Journal of Computer Assisted Tomography, 46, 447-454. [Google Scholar] [CrossRef] [PubMed]
[3] Morita, K., Karashima, S., Terao, T., Yoshida, K., Yamashita, T., Yoroidaka, T., et al. (2024) 3D CNN-Based Deep Learning Model-Based Explanatory Prognostication in Patients with Multiple Myeloma Using Whole-Body MRI. Journal of Medical Systems, 48, Article No. 30. [Google Scholar] [CrossRef] [PubMed]
[4] Mohan Lal, B., van Rhee, F. and Al Hadidi, S. (2025) Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma. Current Oncology Reports, 27, 258-277. [Google Scholar] [CrossRef] [PubMed]
[5] Soekojo, C.Y., Chung, T., Furqan, M.S. and Chng, W.J. (2022) Genomic Characterization of Functional High-Risk Multiple Myeloma Patients. Blood Cancer Journal, 12, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[6] Caro, J., Al Hadidi, S., Usmani, S., Yee, A.J., Raje, N. and Davies, F.E. (2021) How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book, 41, 291-309. [Google Scholar] [CrossRef] [PubMed]
[7] Dingli, D., Ailawadhi, S., Bergsagel, P.L., Buadi, F.K., Dispenzieri, A., Fonseca, R., et al. (2017) Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 92, 578-598. [Google Scholar] [CrossRef] [PubMed]
[8] (2024) Chinese Expert Consensus on Diagnosis and Treatment of High Risk Multiple Myeloma. Chinese Journal of Hematology, 45, 430-435.
[9] Schenone, D., Dominietto, A., Campi, C., Frassoni, F., Cea, M., Aquino, S., et al. (2021) Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. Diagnostics, 11, Article 1759. [Google Scholar] [CrossRef] [PubMed]
[10] Lee, S., Lee, S., Kim, S., Huh, Y., Lee, J., Lee, K., et al. (2023) Differentiating Multiple Myeloma and Osteolytic Bone Metastases on Contrast-Enhanced Computed Tomography Scans: The Feasibility of Radiomics Analysis. Diagnostics, 13, Article 755. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, J., Wang, C., Guo, W., Zeng, P., Liu, Y., Lang, N., et al. (2021) A Preliminary Study Using Spinal MRI-Based Radiomics to Predict High-Risk Cytogenetic Abnormalities in Multiple Myeloma. La Radiologia Medica, 126, 1226-1235. [Google Scholar] [CrossRef] [PubMed]
[12] Wennmann, M., Ming, W., Bauer, F., Chmelik, J., Klein, A., Uhlenbrock, C., et al. (2023) Prediction of Bone Marrow Biopsy Results from MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics. Investigative Radiology, 58, 754-765. [Google Scholar] [CrossRef] [PubMed]
[13] Huang, L., Zhao, Z., An, L., Gong, Y., Wang, Y., Yang, Q., et al. (2024) 2.5D Transfer Deep Learning Model for Segmentation of Contrast-Enhancing Lesions on Brain Magnetic Resonance Imaging of Multiple Sclerosis and Neuromyelitis OPTICA Spectrum Disorder. Quantitative Imaging in Medicine and Surgery, 14, 273-290. [Google Scholar] [CrossRef] [PubMed]
[14] Zhang, Y., Chen, Z., Bu, Y., Lei, P., Yang, W. and Zhang, W. (2024) Construction of a 2.5D Deep Learning Model for Predicting Early Postoperative Recurrence of Hepatocellular Carcinoma Using Multi-View and Multi-Phase CT Images. Journal of Hepatocellular Carcinoma, 11, 2223-2239. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, S., Liu, C., Pan, H., Li, S., Teng, P., Li, Z., et al. (2025) Magnetic Resonance Imaging-Based Nomograms Predict High-Risk Cytogenetic Abnormalities in Multiple Myeloma: A Two-Centre Study. Clinical Radiology, 82, Article 106768. [Google Scholar] [CrossRef] [PubMed]
[16] Kumar, S.K., Jacobus, S.J., Cohen, A.D., Weiss, M., Callander, N., Singh, A.K., et al. (2020) Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial. The Lancet Oncology, 21, 1317-1330. [Google Scholar] [CrossRef] [PubMed]
[17] Rajkumar, S.V. (2024) Multiple Myeloma: 2024 Update on Diagnosis, Risk-Stratification, and Management. American Journal of Hematology, 99, 1802-1824. [Google Scholar] [CrossRef] [PubMed]
[18] Facon, T., Venner, C.P., Bahlis, N.J., Offner, F., White, D.J., Karlin, L., et al. (2021) Oral Ixazomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 137, 3616-3628. [Google Scholar] [CrossRef] [PubMed]
[19] Mateos, M., Cavo, M., Blade, J., Dimopoulos, M.A., Suzuki, K., Jakubowiak, A., et al. (2020) Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 395, 132-141. [Google Scholar] [CrossRef] [PubMed]
[20] Callander, N.S., Baljevic, M., Adekola, K., Anderson, L.D., Campagnaro, E., Castillo, J.J., et al. (2022) NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. Journal of the National Comprehensive Cancer Network, 20, 8-19. [Google Scholar] [CrossRef] [PubMed]
[21] Smith, S.C., Althof, P.A., Dave, B.J. and Sanmann, J.N. (2020) High-Risk Cytogenetics in Multiple Myeloma: Further Scrutiny of Deletions within the IGH Gene Region Enhances Risk Stratification. Genes, Chromosomes and Cancer, 59, 569-574. [Google Scholar] [CrossRef] [PubMed]
[22] Kumar, S.K., Rajkumar, V., Kyle, R.A., van Duin, M., Sonneveld, P., Mateos, M., et al. (2017) Multiple Myeloma. Nature Reviews Disease Primers, 3, Article No. 17046. [Google Scholar] [CrossRef] [PubMed]
[23] Cowan, A.J., Green, D.J., Kwok, M., Lee, S., Coffey, D.G., Holmberg, L.A., et al. (2022) Diagnosis and Management of Multiple Myeloma. JAMA, 327, 464-477. [Google Scholar] [CrossRef] [PubMed]
[24] Zamagni, E., Tacchetti, P. and Cavo, M. (2019) Imaging in Multiple Myeloma: How? When? Blood, 133, 644-651. [Google Scholar] [CrossRef] [PubMed]
[25] Hillengass, J., Fechtner, K., Weber, M., Bäuerle, T., Ayyaz, S., Heiss, C., et al. (2010) Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients with Asymptomatic Multiple Myeloma. Journal of Clinical Oncology, 28, 1606-1610. [Google Scholar] [CrossRef] [PubMed]
[26] Litjens, G., Kooi, T., Bejnordi, B.E., Setio, A.A.A., Ciompi, F., Ghafoorian, M., et al. (2017) A Survey on Deep Learning in Medical Image Analysis. Medical Image Analysis, 42, 60-88. [Google Scholar] [CrossRef] [PubMed]
[27] Truhn, D., Schrading, S., Haarburger, C., Schneider, H., Merhof, D. and Kuhl, C. (2019) Radiomic versus Convolutional Neural Networks Analysis for Classification of Contrast-Enhancing Lesions at Multiparametric Breast MRI. Radiology, 290, 290-297. [Google Scholar] [CrossRef] [PubMed]
[28] Staartjes, V.E., de Wispelaere, M.P., Vandertop, W.P. and Schröder, M.L. (2019) Deep Learning-Based Preoperative Predictive Analytics for Patient-Reported Outcomes Following Lumbar Discectomy: Feasibility of Center-Specific Modeling. The Spine Journal, 19, 853-861. [Google Scholar] [CrossRef] [PubMed]
[29] Mohsen, F., Ali, H., El Hajj, N. and Shah, Z. (2022) Artificial Intelligence-Based Methods for Fusion of Electronic Health Records and Imaging Data. Scientific Reports, 12, Article No. 17981. [Google Scholar] [CrossRef] [PubMed]